© Drug Hunter Inc. 2018-2023
Home > OI338
oral, ultralong-acting insulin analog
effective in Ph. IIa, hum. t1/2~3 d, 4% F dog
albumin-binding motif + reduced endocytosis
J. Med. Chem., Dec. 28, 2020
Novo Nordisk, Maaloev, DK
Novo oral insulin analog
Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.
Request a trial to access insights powering the pros in our industry.
Molecules of the Month
Molecule of the Year